Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI res...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Naumov, George N., Nilsson, Monique B., Cascone, Tina, Briggs, Alexandra, Straume, Oddbjorn, Akslen, Lars A., Lifshits, Eugene, Byers, Lauren Averett, Xu, Li, Wu, Hua-kang, Jänne, Pasi, Kobayashi, Susumu, Halmos, Balazs, Tenen, Daniel, Tang, Xi M., Engelman, Jeffrey, Yeap, Beow, Folkman, Judah, Johnson, Bruce E., Heymach, John V.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893040/
https://ncbi.nlm.nih.gov/pubmed/19447865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2904
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki